Home › with Excess of Blasts Refractory Anemia › Washington › Seattle
with Excess of Blasts Refractory Anemia clinical trials in Seattle, WA
5 studies for with Excess of Blasts Refractory Anemia are looking for participants at sites in and around Seattle (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
RecruitingPhase 1/2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
RecruitingPhase 1/2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
RecruitingPhase 2/3
- Seattle Cancer Care Alliance, Seattle
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
RecruitingPhase 2
- Fred Hutchinson Cancer Center, Seattle
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
RecruitingPhase 2
- Fred Hutchinson Cancer Research Center, Seattle
with Excess of Blasts Refractory Anemia trials in other cities
- Houston, TX6 studies
- New York City, NY3 studies
- Boston, MA3 studies
- Washington, DC3 studies
- Columbus, OH3 studies
Other studies in Seattle
- Non-Small Cell Lung Cancer53 studies
- Cancer (all types)49 studies
- Prostate Cancer42 studies
- Acute Myeloid Leukemia41 studies
- Breast Cancer39 studies
- Metastatic Cancer39 studies
- Colorectal Cancer34 studies
- Lung Cancer33 studies
- Ovarian Cancer30 studies
- Multiple Myeloma22 studies
- Bladder Cancer21 studies
- Myelodysplastic Syndromes21 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.